News | November 10, 2025
Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
Venus Remedies now has 29 active product approvals in Vietnam alone
Venus Remedies now has 29 active product approvals in Vietnam alone
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
This surpasses the number of approvals supported in 2020
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Bourgoin early development hub broadens offerings for oral solid dose formulations
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Subscribe To Our Newsletter & Stay Updated
